In this article
Shares of Novo Nordisk
rose more than 5% on Friday after early prescription data showed an encouraging start to the U.S. launch of the company’s new GLP-1 pill for obesity.
In a Friday note, TD Cowen analysts called it a “solid start” for the first-ever weight loss pill, but said “one data point does not make a trend.” They cautioned that they need to see more data to fully assess what early demand is like for the Wegovy pill, which officially launched on Jan. 5 after winning approval in late December.
Still, the initial data is a boost to the Danish drugmaker’s hopes of winning back more market share from its chief rival, Eli Lilly
